Rentschler Biotechnologie transitions into a European corporation called Rentschler Biopharma SE

9 Oct 2017

This legal form of company strengthens its position as a full-service CDMO and ensures its place as an industry leader.

Rentschler Biotechnologie has announced that the company has successfully transitioned into a European corporation (SE) with entry into the German commercial register on 1 October 2017. The company is operating as Rentschler Biopharma SE with immediate effect. There will be no operational changes for clients or employees of the family-owned company due to the transition.

Rentschler Biotechnologie transitions into a European corporation called Rentschler Biopharma SE

“With our transition to Rentschler Biopharma SE, we emphasize our long-term international corporate identity, while the core business remains unaffected. In future, this legal form of company strengthens our position as a full-service CDMO and ensures our place as a leader in this industry,” commented Prof. Dr Nikolaus F. Rentschler, Owner of Rentschler Biopharma SE. “Our proven service offering along the entire value chain – from bioprocess development through biomanufacturing to fill and finish of biopharmaceuticals – remains unchanged. This also applies to our company sites and manufacturing facilities as well as the existing client relations and importantly their contact persons.”

Over the recent years, Rentschler Biopharma has grown considerably and invested constantly in facilities so that capacities have more than doubled. With the expansion of our facilities, a continually growing number of employees has also been added to the company. About 200 employees have been recruited in all business segments during the past year and a half. In the current fiscal year, over 120 additional positions are to be filled.

Read More

Related tags

Market News

Related news

Aptar Pharma to showcase an industry first

Aptar Pharma to showcase an industry first

12 Sep 2018

PureHale is a new portable drug delivery device designed for upper respiratory care.

Read more 
Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio

11 Sep 2018

The Sandoz US portfolios to be sold to Aurobindo include approximately 300 products, as well as additional development projects.

Read more 
New SGS biopharmaceutical testing capabilities in Illinois

New SGS biopharmaceutical testing capabilities in Illinois

11 Sep 2018

The new services will focus on quality control analysis and stability testing of biopharmaceuticals.

Read more 
Exciting skincare to protect against blue light emitted by phones and devices

Exciting skincare to protect against blue light emitted by phones and devices

10 Sep 2018

Novel, dual-acting product revitalizes and protects skin against blue light and environmental aggressors around the clock.

Read more 
24/7 life science manufacturing IT service launches

24/7 life science manufacturing IT service launches

7 Sep 2018

Faster GMP incident response and resolution times when manufacturing IT applications fail or are not running to their optimum capacity.

Read more 
Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

Catalent signs commercial supply agreement for Aucta Pharmaceuticals' vigabatrin

6 Sep 2018

Novel dosage form employs Catalent’s proprietary stick pack dosage form.

Read more 
Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

Sartorius and Repligen partner to introduce next-generation perfusion-enabled bioreactors

5 Sep 2018

Customers to benefit from simplified, scalable solutions for intensified cell culture.

Read more 
Boehringer Ingelheim to build new tablet manufacturing facility

Boehringer Ingelheim to build new tablet manufacturing facility

4 Sep 2018

Facility to manufacture innovative drugs for worldwide market launches and technologically advanced production.

Read more 
Plasticell wins military contract to develop regenerative medicines for the battlefield

Plasticell wins military contract to develop regenerative medicines for the battlefield

4 Sep 2018

Company to use its combinatorial stem cell screening platform to develop technologies for the conversion of pluripotent stem cells into platelets.

Read more 
Bio processing and manufacturing league table ranks US top and China bottom

Bio processing and manufacturing league table ranks US top and China bottom

3 Sep 2018

US, Germany and Japan revealed as tier one nations in all categories with Sweden ranking the best of the rest.

Read more